AstraZeneca's immunotherapy drug scores key Phase III lung cancer win - MedCity News
AstraZeneca's immunotherapy drug scores key Phase III lung cancer win MedCity News
The company said the Phase III CASPIAN study of Imfinzi in first-line, extensive-stage small-cell lung cancer was successful, but did not disclose further details.
Comments
Post a Comment